EBMT 2023 | Managing early & late relapse after first-line therapy for DLBCL
Marjolein van der Poel, MD, PhD, Maastricht University Medical Center, Maastricht, Netherlands, discusses optimal management strategies for patients with diffuse large B-cell lymphoma (DLBCL) who relapse after first-line treatment. According to Dr van der Poel, patients who relapse within 12 months of treatment and are fit should receive CAR-T therapy and those who are not eligible for CAR-T should be enrolled in clinical trials. Moreover, patients who relapse later and are fit should receive salvage chemotherapy and autologous transplantation and if they are unfit, CAR-T therapy or clinical trials evaluating bispecific antibodies are good alternative options. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda, Kite/Gilead: Honoraria
